The world's first liver cancer immunotherapy study was published in The Lancet Oncology

On June 21, Cinda Biopharmaceuticals announced that Daboshu® (sintilizumab injection) combined with Dayoutong® (bevacizumab injection) for the first-line treatment of advanced liver cancer was randomized, controlled, and open The results of the multi-center phase II/III pivotal clinical study (ORIENT-32) were published in the internationally renowned journal "The Lancet·Oncology"

According to reports, this clinical study is led by Academician Fan Jia from Zhongshan Hospital of Fudan University.

In January 2021, the National Medical Products Administration (NMPA) accepted a new indication for Daboshu® (sintilizumab injection) combined with Dayoutong® (bevacizumab injection) for the treatment of first-line liver cancer patients Listing application (sNDA)

Daboshu® (sintilimab) is a PD-1 inhibitor that has attracted much attention in the field of tumor immunotherapy

Dayoutong® (bevacizumab) is an angiogenesis inhibitor.

The main investigator of the ORIENT-32 study, Professor Fan Jia from Zhongshan Hospital of Fudan University, said that the study published in the journal "Lancet Oncology" reflects the international oncology community’s recognition of this high-quality Chinese original research.